Neurosarcoidosis Workup

  • Author: Gabriel Bucurescu, MD, MS; Chief Editor: B Mark Keegan, MD, FRCPC   more...
 
Updated: Oct 28, 2011
 

Approach Considerations

Definitive diagnosis of neurosarcoidosis requires the exclusion of other causes of neuropathy and the identification of noncaseating sarcoid granulomas by histologic analysis of nerve and muscle biopsy specimens. Other studies and diagnostic procedures may include the following:

  • Blood studies
  • Serum protein immune electrophoresis
  • Lumbar puncture with cerebrospinal fluid (CSF) analysis
  • Chest radiography
  • Magnetic resonance imaging
  • Fluorodeoxyglucose positron emission tomography (FDG-PET)
  • Electromyography/nerve conduction studies (EMG/NCS)
  • Evoked potential (EP) studies

The diagnosis of peripheral neuropathy as a result of sarcoidosis is determined by establishing, in the first instance, the presence of a peripheral neuropathy; excluding the common causes of peripheral neuropathy, such as hyperglycemic states, deficiencies of vitamins, and presence of toxins such as heavy metals; and establishing a pathologic diagnosis of noncaseating granulomas in neural or extraneural sites.

Findings of cerebrospinal fluid analysis are normal in 30% of cases, specifically in patients with cranial nerve and peripheral nerve involvement. When CSF analysis findings are abnormal, they reflect a nonspecific pattern. Serial CSF analyses may be necessary in some cases.

On skin testing, cutaneous anergy can be seen in systemic or active pulmonary sarcoidosis. However, it almost never occurs in pure neurosarcoidosis.

Small-fiber neuropathy may be evaluated by thermal threshold testing (TTT). On the other hand, sympathetic skin responses and cardiac autonomic testing (by Ewing test and iodine-123 meta-iodobenzylguanidine [123 I-MIBG] myocardial scanning) have been reported to have limited diagnostic value for evaluation of small- fiber neuropathy.

Next

Blood Studies

A complete blood count (CBC) with differential may show a variety of changes, as follows.

  • Normochromic normocytic anemia
  • Megaloblastic changes
  • Basophilic stippling
  • Other dyshematopoietic states
  • Lymphopenia

The erythrocyte sedimentation rate (ESR) may be elevated in systemic sarcoidosis. Creatine kinase, ESR, and aldolase may be useful in cases of myopathy.

Tests for hyperglycemic states should be performed, including fasting glucose and glycosylated hemoglobin levels to exclude diabetes mellitus. If those results are normal, a 2-hour oral glucose tolerance test is needed.

A serum vitamin B-12 level should be measured to exclude deficiency. If the level is on the low side, the diagnosis should be pursued by measuring serum homocysteine and methylmalonic acid levels, which are expected to be high in B-12 deficiency.

Blood urea nitrogen (BUN), creatinine, and serum calcium should be checked to rule out long-standing metabolic derangements, which can result in neuropathy. Hypercalcemia is a known feature of systemic sarcoidosis, and abnormalities of renal functions may reflect a wider involvement of the primary disease process.

Liver function tests (eg, alanine aminotransferase, aspartate aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase), if abnormal, may reflect systemic involvement by either sarcoidosis or other diseases. Antineutrophil cytoplasmic antibody (C-ANCA) titers may be needed to differentiate neurosarcoidosis from Wegener granulomatosis.

Previous
Next

Endocrine Studies

Endocrine studies should be performed whenever involvement of the pituitary-hypothalamic axis is suspected. This includes tests of the following:

  • Thyroid function
  • Prolactin
  • Testosterone
  • Growth hormone
  • Luteinizing hormone
  • Follicle-stimulating hormone
  • Corticotropin-releasing hormone
  • Estradiol
  • Urine osmolality
  • Insulinlike growth factor
Previous
Next

Chest Radiography

Chest radiography often demonstrates perihilar lymphadenopathy or the interstitial lung disease of sarcoidosis. These abnormalities also may suggest lymphoma or other systemic diseases. See the images below.

Early chest radiograph findings in sarcoidosis. Early chest radiograph findings in sarcoidosis. Advanced chest radiograph findings in sarcoidosis.Advanced chest radiograph findings in sarcoidosis.
Previous
Next

Magnetic Resonance Imaging

MRI scans of the brain and spine are indispensable in assessing nervous system involvement. Imaging studies of specific regions or organ systems may be appropriate if clinically indicated or if laboratory testing suggests involvement of that organ system. Although computed tomography may also be used, MRI has become the modality of choice because of the superior images obtained.

The use of gadolinium and fluid-attenuated inversion recovery (FLAIR) has increased the sensitivity of an MRI, helping identify T2 enhancement of nerve roots, plexuses, and limb nerves. MRI of peripheral nerves may occasionally show a diffusely enlarged nerve as a soft tissue mass.

Some series have shown that gadolinium enhancement demonstrated leptomeningeal involvement in cases that unenhanced images might have missed. The enhancement can follow the contour of the brain, extending into the cortical sulci. Gadolinium also can leak into the contiguous CSF because of disruption of capillary endothelial tight junctions of the arachnoid matter.

A thick and ragged pial enhancement is indicative of invasion along perivascular spaces, leading to a meningoencephalovasculopathy. Enhancement of linear and nodular areas from the pial surface into the white matter indicates infiltration along Virchow-Robin spaces.

In the FLAIR technique, the signal from the CSF is suppressed, and mild or heavy T2 weighting (long TE) is used to detect lesions. This technique is of value in detecting low-contrast lesions. It also can be used to improve the accuracy of detecting T2 prolongation in the temporal lobe in cases of mesial temporal sclerosis.

The nulling of the CSF signal maximizes the sensitivity of the sequence to changes in the T1 of the CSF. The FLAIR technique is valuable in diffusion weighting and is especially sensitive to contrast enhancement. It also can be combined with fat suppression.

An MRI may demonstrate the following:

  • Periventricular high-signal lesions on T2-weighted images
  • Multiple supratentorial and infratentorial brain lesions
  • Solitary intra-axial mass
  • Solitary extra-axial mass
  • Leptomeningeal enhancement
  • Optic nerve enhancement (see the images below)
  • Spinal cord intramedullary mass resembling demyelinating diseaseMRI of the brain in a 37-year-old man with neurosaMRI of the brain in a 37-year-old man with neurosarcoidosis who had complete loss of vision in the right eye for 2 months and occasional blurry vision in the left. T1-weighted sagittal image shows intact optic nerves. MRI of the brain in a 37-year-old man with neurosaMRI of the brain in a 37-year-old man with neurosarcoidosis who had complete loss of vision in the right eye and mild left eye blurriness. This fluid-attenuated inversion recovery (FLAIR) axial image shows a wedge-shaped area of infarction in the right temporo-occipital area. The optic nerves exhibit abnormal signal. MRI of the brain in a 37-year-old patient with sarMRI of the brain in a 37-year-old patient with sarcoidosis who had right eye blindness and mild blurry vision in the left eye. This postgadolinium, T1-weighted axial image shows right optic nerve enhancement along almost the entire intraorbital portion and a small amount in the prechiasmatic portion. The left optic nerve enhances from the level of the optic chiasm to the distal intraorbital portion. The right temporo-occipital infarct is seen as a faint hypodensity; it does not enhance after gadolinium administration. MRI of the brain in a 37-year-old man with sarcoidMRI of the brain in a 37-year-old man with sarcoidosis who had loss of vision in the right eye and blurry vision in the left. This postgadolinium, T1-weighted axial image shows abnormal enhancement of both optic nerves, with the left optic nerve appearing worse on this study than in the study shown as Picture 5, which was done 6 months earlier. The right temporo-occipital hypodensity represents the old infarction.
Previous
Next

Positron Emission Tomography

Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging may show areas of hypermetabolism or hypometabolism in the central nervous system, and this information may be compared to a systemic PET scan in patients with systemic sarcoidosis, thus establishing a firmer diagnosis. However, because the brain has high metabolic activity, it may be difficult to interpret PET imaging in the evaluation of neurosarcoidosis. Whole-body FDG-PET was fojnd to be more sensitive than gallium scanning for assessing activity of sarcoidosis.[25] It has proven of great value in detecting occult diagnostic biopsy sites and in assessing residual activity in fibrotic pulmonary sarcoidosis and may help in making therapeutic decisions.

Whole-body FDG-PET scanning may reveal otherwise occult/subclinical areas of involvement, demonstrate the extent of disease, and suggest possible biopsy sites.

The combination of FDG- and F-18 fluorothymidine (FLT) PET/CT scanning can help in differentiating neurosarcoidosis from malignancy and in localizing biopsy sites.[26]

Previous
Next

Electromyography/Nerve Conduction Studies

Electromyography/nerve conduction studies (EMG/NCS) can be used to confirm neuropathy. Findings include slowing of motor nerve conduction velocities, as well as abnormal sensory nerve conduction consisting of absent potentials, reduced amplitude, and mild slowing. Mixed compound nerve action potentials may be seen as well.

The most characteristic electrodiagnostic finding is mononeuropathy multiplex, showing axonal degeneration and segmental demyelination. In cases of myopathy, the EMG shows myopathic potentials. With treatment and clinical improvement, motor, sensory, and mixed nerve conduction tend to improve.

Previous
Next

Evoked Potential Studies

Evoked potential studies may be of value in supporting the diagnosis and in monitoring the course of the disease. Visual evoked potentials (VEPs) and brainstem auditory evoked potentials (BAEPs) tend to be abnormal in about one third of the patients with neurosarcoidosis.

Somatosensory evoked potentials tend to show abnormalities less frequently. All 3 modalities of EPs can show abnormalities in patients before the appearance of clinical signs.

Previous
Next

CSF Analysis

When the involvement is purely peripheral (eg, diffuse peripheral neuropathy or myopathy), the CSF findings are normal. CSF examination shows a nonspecific pattern of pleocytosis and elevated protein (>0.5 g/L) if the root sheaths or meninges are involved. Glucose levels may be normal or low. In one study of 68 patients, the CSF leukocyte count was in the range of 5-220 cells/µL. These CSF findings, coupled with negative cytology and culture results, support the diagnosis of neurosarcoidosis.

levels of angiotensin-converting enzyme (ACE), lysozyme, and beta2-microglobulin can be elevated in the CSF in more than half the patients; changes in these markers can parallel the clinical course. The ACE level is rarely elevated in isolated neuropathy but may be elevated in systemic sarcoidosis.

High IgG, Ig index, and oligoclonal bands have been reported in the CSF. Studies of subpopulations of T lymphocytes have shown a high T4/T8 ratio, which can help in differentiating sarcoidosis from multiple sclerosis.

A recent study reported elevated levels of soluble CSF interleukin 2 receptor (sIL2-R) in patients with neurosarcoidosis, suggesting this as a possible marker for the diagnosis of the disease and for treatment and follow up of disease activity.[27]

Previous
Next

Biopsy

Biopsy of an enlarged lymph node or an active area on gallium scan may reveal noncaseating granulomas, which suggest sarcoidosis as the pathologic etiology. Biopsy of the sural nerve may reveal fiber loss with a combination of axonal injury and demyelination.

Biopsies show granulomas surrounded by normal muscle in 50-80% of asymptomatic patients. A case report of neurosarcoidosis (sarcoid brainstem encephalitis) demonstrated nemaline rods in every muscle examined.[28]

Because the granulomas can be scarce, a large sample should be taken. Granulomas are not specific for neurosarcoidosis and can be seen in patients with tuberculosis, fungal infections, collagen vascular disorders, or carcinoma.

In symptomatic patients, nodules are less frequent. In some cases, noncaseous granulomatous myositis or chronic myopathic changes can be seen. Peripheral nerve biopsies may show segmental demyelination, degenerating nerve roots with inflammatory cells, axonal degeneration, and mechanical destruction of nerves by granulomas.

Brain biopsy may be required in selected patients with isolated brain involvement. In other cases, the patient's history, MRI scans, and chest radiograph may be sufficient for arriving at the correct diagnosis. Blood vessel biopsies of both arteries and veins can show involvement of the vessel wall, most frequently in the perforating arteries.

Previous
Next

Histologic Findings

The diagnostic hallmark of sarcoidosis is the presence of granulomas in the involved tissue (see the images below). Granulomas are predominantly noncaseating (or solid), discrete, and naked, with a relative paucity of lymphocytes and plasma cells in the periphery. Nerve biopsy reveals secondary axonal degeneration with atrophy of nerve fibers. Myelin ovoids, which suggest demyelination, are occasionally seen.[29]

Noncaseating granuloma surrounded by epithelioid cNoncaseating granuloma surrounded by epithelioid cells, from the medulla oblongata. Also shown are nodular inflammatory infiltrates consisting of multinucleated giant cells, macrophages, and lymphocytes (hematoxylin and eosin, 40x). Noncaseating granuloma in medulla oblongata showinNoncaseating granuloma in medulla oblongata showing the granuloma surrounded by epithelioid cells and nodular inflammatory infiltrates (hematoxylin and eosin, 20x).

In a review by Vital et al of neuropathologic findings in 38 cases of sarcoid neuropathy, the characteristic noncaseating granulomas were found on the nerve in 11 cases, on the muscle alone in 5 cases, on both muscle and nerve in 10 cases, and in the nerve and another parenchyma (mainly lung or lymph node) in 12 cases. These cases included chronic sensory motor neuropathy, mononeuropathy multiplex, painful neuropathy, and atypical chronic inflammatory demyelinating polyneuropathy (CIDP).[30]

Moreover, necrotizing vasculitis was present in nerve biopsies from 8 cases and microvasculitis without obvious necrosis in 2 cases. Vital et al concluded that nerve fiber lesions, which are mainly axonal, are probably related to mechanical compression by noncaseating granulomas and/or to an ischemic process due to vasculitis. Cytokines and immune factors may also play a role, especially in certain cases with a clinical presentation of CIDP.[30]

In a separate series, Said et al found epineurial granulomas and perineuritis in all nerve specimens in 11 patients. The inflammatory infiltrates invaded the endoneurium, following connective tissue septae and blood vessels, in 5 patients. Multinucleated giant cells were found in 8 patients, and necrotizing vasculitis was found in 7. Inflammatory lesions were associated with variable, asymmetrical involvement of nerve fascicles and axon loss.[31]

A muscle specimen sampled during the same sitting in 10 patients showed inflammatory infiltrates and granulomas in 9 patients and necrotizing vasculitis in 2. Immunolabeling showed a mixed inflammatory infiltrate of T cells (predominantly CD4+ cells) and macrophages, in keeping with a delayed hypersensitivity reaction.[31] A case report by Bos et al revealed that nemaline rods can be found on muscle biopsy in neurosarcoidosis.[28]

Previous
 
 
Contributor Information and Disclosures
Author

Gabriel Bucurescu, MD, MS  Staff Neurologist, Neurology Service, Philadelphia Veterans Affairs Medical Center

Gabriel Bucurescu, MD, MS is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, and American Epilepsy Society

Disclosure: Nothing to disclose.

Coauthor(s)

Amer Suleman, MD  Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

B Mark Keegan, MD, FRCPC  Assistant Professor of Neurology, College of Medicine, Mayo Clinic; Master's Faculty, Mayo Graduate School; Consultant, Department of Neurology, Mayo Clinic, Rochester

B Mark Keegan, MD, FRCPC is a member of the following medical societies: American Academy of Neurology, American Medical Association, and Minnesota Medical Association

Disclosure: Novartis Consulting fee Consulting; Bionest Consulting fee Consulting

Additional Contributors

Paul E Barkhaus, MD Professor, Department of Neurology, Medical College of Wisconsin; Director of Neuromuscular Diseases, Milwaukee Veterans Affairs Medical Center

Paul E Barkhaus, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association

Disclosure: Nothing to disclose.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

Nicholas Lorenzo, MD Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants

Nicholas Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and American College of Physician Executives

Disclosure: Nothing to disclose.

Haresh Mani, MD Assistant Professor, Department of Pathology, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine

Disclosure: Nothing to disclose.

N K Nikhar, MD , MRCP Private Practice

N K Nikhar, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Amy A Pruitt, MD Associate Professor of Neurology, University of Pennsylvania; Attending Neurologist, Hospital of the University of Pennsylvania

Amy A Pruitt, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Florian P Thomas, MD, MA, PhD, Drmed Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Paraplegia Society, and National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

References
  1. Voorter CE, Drent M, Hoitsma E, Faber KG, van den Berg-Loonen EM. Association of HLA DQB1 0602 in sarcoidosis patients with small fiber neuropathy. Sarcoidosis Vasc Diffuse Lung Dis. Jun 2005;22(2):129-32. [Medline].

  2. Desestret V, Didelot A, Meyronet D, Bruyas A, Jouvet A, Honnorat J. Neurosarcoidosis with diencephalitis and anti-Ma2 antibodies. Neurology. Mar 2 2010;74(9):772-4. [Medline].

  3. Kobayashi D, Rouster-Stevens K, Harper A. La crosse virus encephalitis preceding neurosarcoidosis diagnosed by brain biopsy. Pediatrics. Apr 2011;127(4):e1091-6. [Medline].

  4. Motta M, Alongi F, Bolognesi A, Cozzarini C, Di Muzio N, Fazio F. Remission of refractory neurosarcoidosis treated with brain radiotherapy: a case report and a literature review. Neurologist. Mar 2008;14(2):120-4. [Medline].

  5. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. Mar 2009;80(3):297-304. [Medline].

  6. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. Jun 2003;20(2):118-25. [Medline].

  7. Byard RW, Manton N, Tsokos M. Sarcoidosis and mechanisms of unexpected death. J Forensic Sci. Mar 2008;53(2):460-4. [Medline].

  8. Petropoulos IK, Zuber JP, Guex-Crosier Y. Heerfordt syndrome with unilateral facial nerve palsy: a rare presentation of sarcoidosis. Klin Monbl Augenheilkd. May 2008;225(5):453-6. [Medline].

  9. Niemer GW, Bolster MB, Buxbaum L, Judson MA. Carpal tunnel syndrome in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. Oct 2001;18(3):296-300. [Medline].

  10. SHAMBAUGH GE, CIRKSENA WJ, NEWCOMER KL. CARPAL TUNNEL SYNDROME AS MANIFESTATION OF SARCOIDOSIS. Arch Intern Med. Dec 1964;114:830-3. [Medline].

  11. Nakatani-Enomoto S, Aizawa H, Koyama S, Kuroda K, Kimura T, Kikuchi K. Transient swelling of peripheral nerves in a case of neurosarcoidosis. Intern Med. Nov 2004;43(11):1078-81. [Medline].

  12. Colvin IB. Audiovestibular manifestations of sarcoidosis: a review of the literature. Laryngoscope. Jan 2006;116(1):75-82. [Medline].

  13. Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci. May 15 2006;244(1-2):77-87. [Medline].

  14. Brigger MT, McLeod IK, Sorensen MP. Neurosarcoidosis presenting as complicated sinusitis: a case report and review. Ear Nose Throat J. Feb 2008;87(2):93-5. [Medline].

  15. Parthasarathy K, Wu J, Vigneswaran N. Oral and maxillofacial pathology case of the month. Neurosarcoidosis. Tex Dent J. Aug 2010;127(8):786-9. [Medline].

  16. Miura S, Kusumoto M, Noda K, Azuma K, Toda R, Honda S, et al. Bell-shaped sensory impairments of all modalities in a neurosarcoidosis patient. Clin Neurol Neurosurg. Nov 2007;109(9):794-8. [Medline].

  17. Nakazato Y, Kondo S, Ohkuma A, Ito Y, Tamura N, Araki N. Neurosarcoidosis presenting as spontaneously remitting hypersomnia. J Neurol. Nov 2009;256(11):1929-31. [Medline].

  18. Afshar K, Engelfried K, Sharma OP. Sarcoidosis: a rare cause of Kleine-Levine-Critchley syndrome. Sarcoidosis Vasc Diffuse Lung Dis. Sep 2008;25(1):60-3. [Medline].

  19. Papapetropoulos S, Guevara A, Georgiou M, Mitsi G, Singer C, Delgado S. Sarcoidosis with basal ganglial infiltration presenting as Parkinsonism. BMJ Case Rep. 2009;2009:[Medline]. [Full Text].

  20. Lee CH, Jung YS, Lee SH. Hydrocephalus as a presenting manifestation of neurosarcoidosis : easy to misdiagnose as tuberculosis. J Korean Neurosurg Soc. Jul 2010;48(1):79-81. [Medline]. [Full Text].

  21. D'Errico S, Bello S, Cantatore S, Neri M, Riezzo I, Turillazzi E, et al. Immunohistochemical characterisation and TNF-a expression of the granulomatous infiltration of the brainstem in a case of sudden death due to neurosarcoidosis. Forensic Sci Int. May 20 2011;208(1-3):e1-5. [Medline].

  22. Hoitsma E, Faber CG, van Kroonenburgh MJ, Gorgels AP, Halders SG, Heidendal GA, et al. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. Mar 2005;22(1):43-50. [Medline].

  23. Uzawa A, Kojima S, Yonezu T, Kanesaka T. Truncal polyradiculopathy due to sarcoidosis. J Neurol Sci. Jun 15 2009;281(1-2):108-9. [Medline].

  24. Jain V, Deshmukh A, Gollomp S. Bilateral facial paralysis: case presentation and discussion of differential diagnosis. J Gen Intern Med. Jul 2006;21(7):C7-10. [Medline]. [Full Text].

  25. Mañá J, Gámez C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. Sep 2011;17(5):325-31. [Medline].

  26. Kim SK, Im HJ, Kim W, Kim TS, Hwangbo B, Kim HJ. F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. Clin Nucl Med. Feb 2010;35(2):67-70. [Medline].

  27. Petereit HF, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol. Nov 2010;257(11):1855-63. [Medline].

  28. Bos MM, Overeem S, van Engelen BG, Scheffer H, van den Elzen C, Ter Laak H, et al. A case of neuromuscular mimicry. Neuromuscul Disord. Aug 2006;16(8):510-3. [Medline].

  29. Nemni R, Galassi G, Cohen M, Hays AP, Gould R, Singh N, et al. Symmetric sarcoid polyneuropathy: analysis of a sural nerve biopsy. Neurology. Oct 1981;31(10):1217-23. [Medline].

  30. Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol. Mar-Apr 2008;27(2):96-105. [Medline].

  31. Said G, Lacroix C, Planté-Bordeneuve V, Le Page L, Pico F, Presles O, et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain. Feb 2002;125:264-75. [Medline].

  32. Levy Y, Uziel Y, Zandman G, Rotman P, Amital H, Sherer Y, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. Jun 2005;1051:779-86. [Medline].

  33. Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry. Mar 2010;81(3):241-6. [Medline].

  34. Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J. Medically refractory neurosarcoidosis treated with infliximab. Intern Med J. Apr 2011;41(4):354-7. [Medline].

  35. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. Jan 27 2009;72(4):337-40. [Medline]. [Full Text].

  36. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. Aug 10 2010;75(6):568-70. [Medline].

  37. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. Mar 29 2011;76(13):1168-72. [Medline].

  38. Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord. Dec 2007;45(12):802-3. [Medline].

  39. Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. Mar 2006;23(1):73-7. [Medline].

  40. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-Term Treatment with Infliximab in Patients with Sarcoidosis. Respiration. Jul 29 2011;[Medline].

  41. Chintamaneni S, Patel AM, Pegram SB, Patel H, Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol. Jul 2010;13(3):207-10. [Medline]. [Full Text].

  42. Sundaresan P, Jayamohan J. Stereotactic radiotherapy for the treatment of neurosarcoidosis involving the pituitary gland and hypothalamus. J Med Imaging Radiat Oncol. Dec 2008;52(6):622-6. [Medline].

Previous
Next
 
Atrophic right optic disc of a 37-year-old man with neurosarcoidosis and involvement of both optic nerves. Vision was lost. The disc is pale with sharp borders.
Atrophic left optic disc of a 37-year-old patient with neurosarcoidosis and involvement of both optic nerves. The disc is pale with sharp borders. Vision was largely preserved.
MRI of the brain in a 37-year-old man with neurosarcoidosis who had complete loss of vision in the right eye for 2 months and occasional blurry vision in the left. T1-weighted sagittal image shows intact optic nerves.
MRI of the brain in a 37-year-old man with neurosarcoidosis who had complete loss of vision in the right eye and mild left eye blurriness. This fluid-attenuated inversion recovery (FLAIR) axial image shows a wedge-shaped area of infarction in the right temporo-occipital area. The optic nerves exhibit abnormal signal.
MRI of the brain in a 37-year-old patient with sarcoidosis who had right eye blindness and mild blurry vision in the left eye. This postgadolinium, T1-weighted axial image shows right optic nerve enhancement along almost the entire intraorbital portion and a small amount in the prechiasmatic portion. The left optic nerve enhances from the level of the optic chiasm to the distal intraorbital portion. The right temporo-occipital infarct is seen as a faint hypodensity; it does not enhance after gadolinium administration.
MRI of the brain in a 37-year-old man with sarcoidosis who had loss of vision in the right eye and blurry vision in the left eye. This scan was taken 6 months after the scan shown in Pictures 3, 4, and 5. Both the right and left optic nerves are enlarged and show abnormal signal on this T1-weighted axial image. The patient remained on oral prednisone from the time of the first scan and did not exhibit any further loss of vision in the left eye. Vision in the right eye never returned.
MRI of the brain in a 37-year-old man with sarcoidosis who had loss of vision in the right eye and blurry vision in the left. This postgadolinium, T1-weighted axial image shows abnormal enhancement of both optic nerves, with the left optic nerve appearing worse on this study than in the study shown as Picture 5, which was done 6 months earlier. The right temporo-occipital hypodensity represents the old infarction.
Early chest radiograph findings in sarcoidosis.
Advanced chest radiograph findings in sarcoidosis.
Noncaseating granuloma surrounded by epithelioid cells, from the medulla oblongata. Also shown are nodular inflammatory infiltrates consisting of multinucleated giant cells, macrophages, and lymphocytes (hematoxylin and eosin, 40x).
Noncaseating granuloma in medulla oblongata showing the granuloma surrounded by epithelioid cells and nodular inflammatory infiltrates (hematoxylin and eosin, 20x).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.